Last updated on February 2018

A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Castration-Resistant Prostate Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male

Inclusion Criteria:

  • Written informed consent obtained prior to the initiation of study procedures.
  • Men 18 years of age.
  • Histologically documented prostatic adenocarcinoma.
  • History of Castration-Resistant Prostate Cancer.

Exclusion Criteria:

  • Known M1 disease.
  • Undergone imaging study for metastatic prostate cancer 3 months.
  • ECOG performance status 3.
  • Known malignant pleural effusions or ascites.
  • Current or prior treatment with investigational therapy for M0 Castration-Resistant Prostate Cancer (Taxotere (docetaxel), Provenge (sipuleucel-T), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Jevtana (cabazitaxel), or Xofigo (radium Ra 223 dichloride).

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.